Dapagliflozin aids glycemic control in type 2 diabetes

Dapagliflozin aids glycemic control in type 2 diabetes

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research published in the March 20 issue of the Annals of Internal Medicine.

To evaluate the efficacy and safety of dapagliflozin, John P.H. Wilding, D.M., of University Hospital Aintree in Liverpool, U.K., and associates randomly assigned 800 patients with inadequately controlled , receiving at least 30 units of insulin daily, with or without up to two oral antidiabetic drugs, to receive a daily dose of dapagliflozin (2.5, 5, or 10 mg) or placebo for 48 weeks.

After 24 weeks, the researchers found that patients taking dapagliflozin had a 0.79 to 0.96 percent decrease in mean hemoglobin A1c, compared with a 0.39 percent decrease with placebo. The daily insulin dose decreased by 0.63 units with dapagliflozin compared with an increase of 5.65 units in the . Dapagliflozin was associated with a decrease of 0.92 to 1.61 kg in body weight, compared with an increase of 0.43 kg in the placebo group. At 48 weeks, these effects were maintained. Patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes compared with the placebo group (56.6 versus 51.8 percent).

"Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major in patients with inadequately controlled ," the authors write.

The study was funded by AstraZeneca and Bristol-Myers Squibb, co-developers of dapagliflozin. Several of the authors are employees of AstraZeneca.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Blood glucose levels set for achieving HbA1c targets

Apr 11, 2014

(HealthDay)—The average self-monitored blood glucose (SMBG) concentrations needed at premeal, postmeal, and bedtime have been established to achieve a range of hemoglobin A1c (HbA1c) targets, according ...

Women with diabetes less likely to have a mammogram

Apr 11, 2014

Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's ...

Nonalcoholic fatty liver disease linked to CKD in T1DM

Apr 09, 2014

(HealthDay)—For patients with type 1 diabetes, nonalcoholic fatty liver disease (NAFLD) is independently associated with the risk of incident chronic kidney disease (CKD), according to a study published ...

User comments